<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01161914</url>
  </required_header>
  <id_info>
    <org_study_id>ISU302-2008</org_study_id>
    <nct_id>NCT01161914</nct_id>
  </id_info>
  <brief_title>The Safety and Efficacy Study of ISU302 in Patient With Type I Gaucher Disease</brief_title>
  <official_title>A Multi-national Randomized Double Blinded Phase III Study to Evaluate the Safety and Efficacy of ISU302(Imiglucerase for Injection) or Cerezyme in Patient With Type I Gaucher Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ISU Abxis Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ISU Abxis Co., Ltd.</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare and evaluate the efficacy and safety of ISU302, an
      investigational product, and Cerezyme®, comparator, for Type 1 Gaucher Disease patients
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>January 2011</start_date>
  <primary_completion_date type="Anticipated">August 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change in splenic volume compared to baseline</measure>
    <time_frame>one year</time_frame>
    <description>Primary endpoints to demonstrate non-inferiority of ISU302 against Cerezyme® for change in splenic volume compared to baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>change in organ parameters and biochemical value compared to baseline</measure>
    <time_frame>one year</time_frame>
    <description>Change in splenic volume compared to baseline for all subjects enrolled
Change in hemoglobin concentration
Change in platelet counts
Change in liver volume compared to baseline
Change in range variation of liver function test (ALT/AST)
Change in skeletal status improvement level
Change in bone mineral density
Change in biomarkers (acid phosphatase, angiotensin-converting enzyme (ACE) and chitotriosidase)
After the 1st administration, to evaluate pharmacokinetic profile by glucocerebrosidase activity assay</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Gaucher Disease</condition>
  <arm_group>
    <arm_group_label>Cerezyme®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>60 U/kg infusion (every 2 weeks for 24 weeks)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ISU302</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>60 U/kg infusion (every 2 weeks for 24 weeks)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cerezyme®</intervention_name>
    <description>administered by IV infusion for a dose of 60 U/kg</description>
    <arm_group_label>Cerezyme®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ISU302</intervention_name>
    <description>administered by IV infusion for a dose of 60 U/kg</description>
    <arm_group_label>ISU302</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The subjects have a diagnosis of Type I Gaucher Disease

          -  Subjects between 2 years old and 75 years old

          -  Subjects documented with glucocerebrosidase deficiency

          -  Subjects with splenomegaly (as indicated by CT volumetric analysis as 5 times over
             than the standard size (0.2% of total body weight in kilograms))

          -  A hemoglobin concentration level:Male &gt; 12 years of age &lt;12.0 g/dL Female&gt;12 years of
             age&lt;11.0 g/dL Child &gt; 2 years of age and &lt;12 years of age &lt;10.5 g/dL

          -  Platelet count of &lt; 120,000 / ㎣

          -  Treatment-naive to enzyme replacement therapy (ERT) or treatment- experienced subjects
             who have not received ERT in the 12 months before screening and antibody test result
             is negative

          -  Treatment naive to substrate reduction therapy (SRT) or treatment- experienced
             subjects who have not received SRT in the 12 months before screening

          -  Subjects or their spouses who provide consent to use one of following contraception
             methods, or women in menopause. (In this case, menopause is defined as a period after
             12 months from the last menstruation)

          -  Condoms, sponge, foams, jellies, diaphragm, or intrauterine device (Spouse or patient
             who had vasectomy or tubal ligation/ hysterectomy)

          -  Total abstinence from sexual intercourse: Female patient using oral contraceptives
             must use other contraception method (barrier method) also during the trial period and
             after the completion of trial as well as up to 90 days from the conclusion of trial.

          -  The subject or their legal representative has signed the informed consent.

        Exclusion Criteria:

          -  Treatment with any investigational product in 90 days before study entry

          -  Partial or total splenectomy

          -  Subjects who have a serious concurrent disease like infection or who abuse addictive
             drug and substances.

          -  Pregnant and/or breast-feeding women

          -  Presence of Hepatitis B surface antigen or Hepatitis C or the patients show positive
             reaction to human immunodeficiency virus (HIV) type1

          -  Subjects with a history of allergic reaction to Imiglucerase

          -  Subjects with a history of severe pulmonary hypertension caused by Gaucher Disease

          -  Any subject whom the investigator or the sub investigator considers as inad equate for
             this trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>July 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 11, 2010</study_first_submitted>
  <study_first_submitted_qc>July 13, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 14, 2010</study_first_posted>
  <last_update_submitted>August 22, 2016</last_update_submitted>
  <last_update_submitted_qc>August 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 23, 2016</last_update_posted>
  <responsible_party>
    <name_title>Lee, JaeHeung</name_title>
    <organization>ISU ABXIS CO., LTD</organization>
  </responsible_party>
  <keyword>Type I Gaucher</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gaucher Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

